We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarkers of Oral Cancer Discovered

By LabMedica International staff writers
Posted on 30 Apr 2019
Epigenetics, the non-genetic influences on gene expression, is a powerful mechanism capable of altering gene expression in cancer cells without changes to the DNA sequence, and can cause tumor progression.

Oral cancer is known for its high mortality rate in developing countries, but an international team of scientists hope its latest discovery will change that. More...
The team has discovered epigenetic markers that are distinctly different in oral cancer tissues compared to the adjacent healthy tissues in patients.

Collaborating scientists from the University of Otago (Otago, New Zealand) and the Indian Statistical Institute (ISI, Kolkata, India) recruited 16 oral cancer patients in India, who were either tobacco smokers or chewers or of mixed habits, and took samples of both tumor and normal, adjacent tissue from them.

The team isolating the DNA in the samples, and discovered regions with altered epigenetic profiles in tumors cells compared to normal cells. They looked at one epigenetic mechanism, DNA methylation, which refers to the addition of methyl groups to DNA, like bookmarks. A total of 4,310 unique differentially methylated regions, mapping to 144 miRNA loci, were identified. Three distinct groups of miRNAs were differentially methylated in cancer tissues from smokers, chewers and mixed habitués. Hypermethylation of miR-503, miR-200a/b, miR-320b and miR-489 was associated with worse 5-year survival.

How these bookmarks are arranged could dictate the expression of genes and the spread of abnormal cells. Late diagnosis and poor prognosis are key problems associated with the high mortality rate of this cancer in developing countries. Of the 300,000 cases of tobacco associated oral cancer detected globally, 86% are from India. Aniruddha Chatterjee, PhD, a senior research fellow and co-author of the study, said, “This phenomenon is relatively new and under studied, particularly in oral cancer. This study is one of the first to identify epigenetic markers in oral cancer, using cutting-edge approaches.”

Roshni Roy, PhD, the lead author of the study, added, “We were also surprised to see that small molecules, called microRNA, were methylated or demethylated in the tumors from smokers or chewers or mixed habitués, suggesting that therapeutic intervention might be different in patients depending on the way the tobacco was abused.” The study was published on March 15, 2019, in the journal Epigenomics.

Related Links:
University of Otago
Indian Statistical Institute


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.